Just reading the August newsletter from imm. Interesting read. Marc wrote.The clinical data to date shows efti maybe uniquely positioned to address the entire NSCLC patient population regardless what PD-L1 expression. Wow I have not read that b4.
Just reading the August newsletter from imm. Interesting read....
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.005(1.18%) |
Mkt cap ! $511.1M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 43.0¢ | 41.5¢ | $2.818M | 6.626M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 168332 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 129388 | 6 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
43.0¢ |
Change
0.005 ( 0.51 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 43.0¢ | 41.5¢ | 818937 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| IMM (ASX) Chart |